The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 19, 2013

Filed:

Jun. 15, 2010
Applicants:

Edward R. Bacon, Audubon, PA (US);

Thomas R. Bailey, Phoenixville, PA (US);

Nadine C. Becknell, Coatesville, PA (US);

Sankar Chatterjee, Wynnewood, PA (US);

Derek Dunn, Coatesville, PA (US);

Greg A. Hostetler, Newark, DE (US);

Robert L. Hudkins, Chester Springs, PA (US);

Kurt A. Josef, Radnor, PA (US);

Lars J. S. Knutsen, West Chester, PA (US);

Ming Tao, Maple Glen, PA (US);

Allison L. Zulli, Wayne, PA (US);

Inventors:

Edward R. Bacon, Audubon, PA (US);

Thomas R. Bailey, Phoenixville, PA (US);

Nadine C. Becknell, Coatesville, PA (US);

Sankar Chatterjee, Wynnewood, PA (US);

Derek Dunn, Coatesville, PA (US);

Greg A. Hostetler, Newark, DE (US);

Robert L. Hudkins, Chester Springs, PA (US);

Kurt A. Josef, Radnor, PA (US);

Lars J. S. Knutsen, West Chester, PA (US);

Ming Tao, Maple Glen, PA (US);

Allison L. Zulli, Wayne, PA (US);

Assignee:

Cephalon, Inc., Frazer, PA (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 403/12 (2006.01); C07D 401/14 (2006.01); A61K 31/501 (2006.01); A61P 25/20 (2006.01); A61P 3/04 (2006.01); A61P 25/18 (2006.01); A61P 29/00 (2006.01); A61P 25/06 (2006.01); A61P 25/24 (2006.01); A61P 25/08 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds and/or their pharmaceutically acceptable salts may be effective in the treatment of diseases or disease states related to the activity of the histamine Hreceptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.


Find Patent Forward Citations

Loading…